We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.80 | 2.06% | 39.70 | 39.15 | 39.80 | 39.35 | 38.85 | 39.05 | 315,724 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 3.1M | -6.51M | -0.0217 | -18.04 | 117.73M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/3/2023 20:51 | Ah, some more deflection from LiarBO! I asked him to supply evidence that I use the name Petroc on LSE and not just Bucolic (which I've stated several times) It now appears that he's made up the whole story, as he has changed the subject since I asked for proof. Yet more evidence that he is just a lying little stock basher who needs to be ignored. I'd say the same as I just said to Amberjudy, but I know the two faced slimy liar will complain to his mates the mods and get my post removed. (As he has done several times before, even though he constantly accuses 'rampers' of doing that). | petroc | |
24/3/2023 19:43 | Why hasnât Petroc mentioned what was said in the rest of the webinar? The part where the âexpertsâ said about some men that âTheir ED, if it is such, can actually be more a loss of confidence that they will be able to perform with their partner. Each of the Profs. felt that Eroxon was a safe alternative to stimulate the younger person's confidenceâWhat an eloquent description of a Placebo! But I thought Eroxon was supposed to stimulate their other head? LOLAs already known âplacebo response rates tend to increase with transdermal gelâSo âA possible interpretation of these trialsâ FM57 and FM71 is that transdermal gels that are massaged in âact entirely by engaging placebo mechanismsâ. So the research âprovides further evidence supporting that gels like Eroxon are just be a potent placebo,https://www. | lbo | |
24/3/2023 18:43 | 'So back to what is relevant and can be substantiated' said LiarBO. So please tell us which thread this Petroc posted on LSE on the 13 March. If I can find him I'll openly apologise for saying you made him up. If you ignore this it will just be chalked up as another of your massive lies, pretending that I have two IDs on LSE. | petroc | |
24/3/2023 18:25 | Hahaha! LiarBO seems to have swallowed it hook, line and sinker! Over on LSE in his guise of LiarBOoth, he once accused me of working for FUM, so I led him on! What a gullible little liar he is! This is a post I made on LSE in Dec 21: OMG, the breath-taking irony of Liarbooth coming out with "Futura need to distance themselves from these rampers before they create more serious reputational damage to Futura." You just couldn't make that up, could you? Liarbooth, whose sole reason for being here is to trash Futura by using lies, distortions, false trails, and just plain rubbish to try and put off new investors across multiple platforms, is concerned that Futura might suffer reputational damage because I've skewered Liarbooth on his massive lie ABOUT VIAGRA ! Well, I'm sure Futura will take all appropriate measures to heed Liarbooth's warning and sack me immediately! Hahahaha! You sad sack, Liarbooth! | petroc | |
24/3/2023 18:21 | Hahaha! LiarBO seems to have swallowed it hook, line and sinker! Over on LSE in his guise of LiarBOoth, he once accused me of working for FUM, so I led him on! What a gullible little liar he is! | petroc | |
24/3/2023 18:19 | FTC And NAD Remind Industry Of Their Authority Over All Health Product Advertising FTC shares jurisdiction with FDA over the marketing of dietary supplements, foods, drugs, medical devices, and other health-related products. Pursuant to a Memorandum of Understanding2 between the two agencies, FDA has primary responsibility over claims that appear on labeling, while FTC has primary responsibility for claims made in advertising. Both agencies require health-related marketing to be truthful and substantiated. Unlike FDA, however, FTC does not distinguish between categories of health-related products or claims in evaluating advertising claims. Rather, according to FTC, "the FTC's approach to the advertising of health-related products is the same regardless of whether, under FDA law, the product is considered a food, a supplement[,] or a drug."3 Moreover, FTC has emphasized that the Memorandum of Understanding does not "limit the FTC's jurisdiction or prohibit the agency from taking action against deceptive labeling claims or obtaining orders that address all forms of marketing, including claims that appear in labeling."4 Ensure Clear and Conspicuous Disclosure—Whe Monitor the Quality of the Evidence—Addit The human clinical trial should have both a treatment group and a control group; The study should be randomized; The study should be double blinded; | lbo | |
24/3/2023 18:19 | LiarBO has also made up this character on LSE called Petroc. I've never seen him over there, and he certainly hasn't posted on the FUM board. | petroc | |
24/3/2023 18:15 | Here is some more of the multi-ID rampers false and misleading claims all over the internet and social mediaThe multi-ID rampers even falsely claimed it was a' new drug' and claiming he works for FUM. Others said they came across FUM from the multi-ID rampers using Telegram to ramp it and other admitted to using BOTS, podcasts etchttps://www.ftc.g | lbo | |
24/3/2023 18:01 | And as per the relevant and applicable ASA rulings have clearly said about claims that cannot be substantiated and are misleading! ‘Because the trial was not placebo-controlled&r ‘There was no statistically significant difference between the outcomes for the treatment group’ concluded that the claim had not been substantiated and was misleading’ (So patients using the eroxon gel device) have never been compared to any adequate and equivalent control group (using an inactive sham device) eg arousal gel. So FM71 ‘study was accordingly not adequate evidence of the efficacyâ€&trad Assessment Upheld The ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation. CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims. There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy Because the trial was not placebo-controlled, we considered AcceleDent had not provided adequate evidence to support the claim AcceleDent, is also clinically proven to reduce the pain and discomfort associated with braces and aligners by up to 71%. We concluded that the claim had not been substantiated and was misleading. On that point the claim breached CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 Medicines, medical devices, health-related products and beauty products. Assessment Upheld The ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation. CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims. There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy | lbo | |
24/3/2023 17:58 | Actually I'm interested in this Petroc on LSE. Why not share some more info about him? Perhaps a few posts he has made. Or have you just made him up? Anyway, you seem to know a lot about the workings of LSE. Thought you'd never been there? | petroc | |
24/3/2023 17:43 | One slimy character in particular to be vigilant of is the omnipresent stock ramper. S/he can be found on almost every discussion board / forum and too many times investors can make bad buy decisions by following the rampers misguided advice. 3. They attack those who disagree with their lofty predictions. They cannot back up their arguments with a rational discussion, so they resort to petty name calling and telling others who disagree with them that they are "full of it." 4. They are not open minded. You cannot have an intelligent discussion with these types. They will do whatever they can to discredit those who disagree with them by spreading false information. They are very often antagonistic. So again all just false and misleading claims form the proven multi-ID ramper that cannot be substantiated with any non deficient evidence! Next he will be claiming I am the major shareholder Lombard odier as that also contains the letters l, b and o. Or hasn’t he done that already under another name and accused me of being the same name! Or what about Bucolic!? That also contains l, B and o! So many proven lies by Petroc! So he is now claiming he is only Petroc on here but not Petroc over there! But he is Bucolic! He.cant even keep up with all his lies or multi-IDs! LOL J777J - 03 Apr 2021 - 11:00:51 - 9264 of 17653 Isnt it funny you are trying to make you are Lombard Odier with your LBO handle,which is identity theft. You are also posting as liambooth on Lse. petroc - 28 Feb 2023 - 11:24:16 - 16672 of 17500 I have one name here - Petroc, and Bucolic on LSE Yet there is a Petroc also over on LSE? Another lie confirmed! Member Info for Petroc Member Since 12th Mar 2021 Member Info for Bucolic Member Since 21st Nov 2019 petroc - 18 Mar 2023 - 16:54:59 - 17374 of 17502 LSE is the bb to visit if you want decent chat about FUM petroc 19 Mar '23 - 16:10 - 17425 of 17427 ˜Bear in mind of course that I work for FUM’ | lbo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions